Abstract
Autosomal dominant hypercholesterolemia (ADH; OMIM144400), a risk factor for coronary heart disease, is characterized by an increase in low-density lipoprotein cholesterol levels that is associated with mutations in the genes LDLR (encoding low-density lipoprotein receptor) or APOB (encoding apolipoprotein B). We mapped a third locus associated with ADH, HCHOLA3 at 1p32, and now report two mutations in the gene PCSK9 (encoding proprotein convertase subtilisin/kexin type 9) that cause ADH. PCSK9 encodes NARC-1 (neural apoptosis regulated convertase), a newly identified human subtilase that is highly expressed in the liver and contributes to cholesterol homeostasis.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates
npj Vaccines Open Access 28 September 2023
-
Efficient prime editing in mouse brain, liver and heart with dual AAVs
Nature Biotechnology Open Access 04 May 2023
-
Different clinical phenotypes of a pair of siblings with familial hypercholesterolemia: a case report and literature review
BMC Cardiovascular Disorders Open Access 01 May 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout


References
Varret, M. et al. Am. J. Hum. Genet. 64, 1378–1387 (1999).
Hunt, S.C. et al. Arterioscler. Thromb. Vasc. Biol. 20, 1089–1093 (2000).
Seidah, N.G. et al. Proc. Natl. Acad. Sci. USA 100, 928–933 (2003).
Brown, M.S. & Goldstein, J.L. Proc. Natl. Acad. Sci. USA 96, 11041–11048 (1999).
Elagoz, A., Benjannet, S., Mammarbassi, A., Wickham, L. & Seidah N.G. J. Biol. Chem. 277, 11265–11275 (2002).
Ruoslahti, E. Annu. Rev. Cell. Dev. Biol. 12, 697–715 (1996).
Acknowledgements
We are indebted to the family members for their cooperation and to C. Mugnier for expert assistance in computing the statistics. This work was supported by grants from Progrès-Institut National de la Santé et de la Recherche Médicale, Pfizer, Fondation de France, Comité Français de Coordination des Recherches sur l'Athérosclérose et le Cholestérol and Canadian Research grants (to N.G.S.). M.A. was supported by grants from Société Française d'Athérosclérose, Comité Français de Coordination des Recherches sur l'Athérosclérose et le Cholestérol, Fondation de la Recherche Médicale, Université René Descartes, Conseil de Recherche de l'Université Saint-Joseph. M.V. was supported by a grant from Société Française d'Athérosclérose and Pfizer. L.V. and D.A. were supported by grants from Ministère de l'Education Nationale de la Recherche et de la Technologie.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Abifadel, M., Varret, M., Rabès, JP. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34, 154–156 (2003). https://doi.org/10.1038/ng1161
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng1161
This article is cited by
-
Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
Cardiovascular Diabetology (2023)
-
High fat diet and PCSK9 knockout modulates lipid profile of the liver and changes the expression of lipid homeostasis related genes
Nutrition & Metabolism (2023)
-
PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity
Journal of Experimental & Clinical Cancer Research (2023)
-
Different clinical phenotypes of a pair of siblings with familial hypercholesterolemia: a case report and literature review
BMC Cardiovascular Disorders (2023)
-
Delivery of low-density lipoprotein from endocytic carriers to mitochondria supports steroidogenesis
Nature Cell Biology (2023)